Results 11 to 20 of about 385 (131)

Clinical Evaluation of Drug–Drug Interactions With Aficamten [PDF]

Clinical and Translational Science
Aficamten is a next‐in‐class small molecule cardiac myosin inhibitor that was recently approved by the United States Food and Drug Administration (FDA) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
Neha Maharao, Donghong Xu, Punag Divanji, Tyrell J. Simkins, Jianlin Li, Camelia Dumitrescu, Priyanka Solanki, Adrienne Griffith, Stephen B. Heitner, Stuart Kupfer, Polina German, Justin D. Lutz   +11 more
doaj   +5 more sources

Toward a Quantitative Understanding of Aficamten Clinical Pharmacology: Population Pharmacokinetic Modeling [PDF]

CPT: Pharmacometrics & Systems Pharmacology
Aficamten is a next‐in‐class, cardiac myosin inhibitor in development as a potential chronic oral treatment for patients with hypertrophic cardiomyopathy (HCM).
Donghong Xu, Hanbin Li, Stephen B. Heitner, Daniel L. Jacoby, Stuart Kupfer, Polina German, Justin Lutz   +6 more
doaj   +5 more sources

Comprehensive Review: Mavacamten and Aficamten in Hypertrophic Cardiomyopathy [PDF]

Biomedicines
Hypertrophic cardiomyopathy (HCM) is the most common monogenic heart disease, with an estimated prevalence of 1:600 in the general population, and is associated with significant morbidity.
Tomasz Tokarek
exaly   +6 more sources

Pharmacokinetics, disposition, and biotransformation of the cardiac myosin inhibitor aficamten in humans

Pharmacology Research and Perspectives
Aficamten, a cardiac myosin inhibitor, is being developed for the treatment of patients with symptomatic hypertrophic cardiomyopathy (HCM). The purpose of this study was to determine the absorption, metabolism, and excretion of aficamten.
Donghong Xu
exaly   +5 more sources

Safety and Efficacy of Mavacamten and Aficamten in Patients With Hypertrophic Cardiomyopathy [PDF]

Journal of the American Heart Association
Background Cardiac myosin inhibitors were recently developed to address the underlying pathophysiology of hypertrophic cardiomyopathy and to improve symptoms and quality of life.
Caroline Coats, Pablo García-Pavía, Ahmad Masri   +2 more
exaly   +7 more sources

Towards a Quantitative Understanding of Aficamten Clinical Pharmacology: Pharmacokinetic‐Cardiodynamic Modeling to Support Safety and Efficacy [PDF]

CPT: Pharmacometrics & Systems Pharmacology
In the phase 3 study SEQUOIA‐HCM (NCT05186818), aficamten, a next‐in‐class cardiac myosin inhibitor, was safe and efficacious in participants with obstructive hypertrophic cardiomyopathy (oHCM). Using pharmacokinetics/pharmacodynamics (PKPD) modeling, we
Justin D. Lutz, Russ Wada, Daniel L. Jacoby, Stephen B. Heitner, Stuart Kupfer, Polina German   +5 more
doaj   +3 more sources

Clinical Evaluation of the Effect of Aficamten on QT/QTc Interval in Healthy Participants [PDF]

Clinical and Translational Science
Aficamten is a next‐in‐class, small‐molecule, cardiac myosin inhibitor in development for treating hypertrophic cardiomyopathy (HCM). This 2‐part study evaluated aficamten's impact on QTc interval in healthy participants.
Neha Maharao, Donghong Xu, Tyrell J. Simkins, Owen Bowles, Genzhou Liu, Youcef Benattia, Adrienne Griffith, Stephen B. Heitner, Stuart Kupfer, Polina German   +9 more
doaj   +3 more sources

Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA‐HCM

Journal of the American Heart Association
Background Aficamten, a novel cardiac myosin inhibitor, reversibly reduces cardiac hypercontractility in obstructive hypertrophic cardiomyopathy. We present a prespecified analysis of the pharmacokinetics, pharmacodynamics, and safety of aficamten in ...
Yushi Wang, , Albree Tower-Rader
exaly   +7 more sources

Efficacy of aficamten in obstructive hypertrophic cardiomyopathy: A systematic review and meta-analysis [PDF]

American Heart Journal Plus
Background: Obstructive hypertrophic cardiomyopathy (oHCM), a morbid hereditary condition, is characterized by asymmetrical intraventricular septum enlargement, obstructing blood flow from the left ventricle outflow tract (LVOT) and lowering cardiac ...
Muhammad Nabeel Saddique, Hamza Irfan, Saad Ashraf, Maria Qadri, Hammad Javaid, Sana Iftikhar, Muhammad Zain ul Haq, Laveeza Fatima, Qasim Mehmood, Anurag Jha, Saad Masood, Muhammad Safiullah, Muhammad Imaz Bhatti, Sheena Shamoon, Javed Iqbal   +14 more
doaj   +4 more sources

Myosin Modulator Aficamten Inhibits Force by Altering Myosin’s Biochemical Activity Without Changing Thick Filament Structure [PDF]

JACC: Basic to Translational Science
Summary: We investigated the effects of aficamten on cardiac muscle structure, biochemical activity, and contractile function. Aficamten does not structurally sequester myosin heads along the thick filament.
Saffie Mohran, PhD, Kristina B. Kooiker, PhD, Ateeqa Naim, BS, Matvey Pilagov, BS, Anthony Asencio, BS, Kyrah L. Turner, BS, Weikang Ma, PhD, Galina Flint, MD., Siyao Jiang, BS, Jing Zhao, BS, Timothy S. McMillen, PhD, Christian Mandrycky, PhD, Max Mahoney-Schaefer, BS, Thomas C. Irving, PhD, Bertrand C.W. Tanner, PhD, Neil M. Kad, PhD, Michael Regnier, PhD, Farid Moussavi-Harami, MD   +17 more
doaj   +2 more sources